Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | PPARD | Q03181 | 4/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CEPT1 | Q9Y6K0 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968598 | 0.94 | ACACB (0.48) | MAPTFFAR1PPARDPPARAGPR119 | |
| SCHEMBL15968518 | 0.88 | FFAR1 (0.42) | MAPTFFAR1PPARDPPARACEPT1 | |
| SCHEMBL15968466 | 0.88 | CEPT1 (0.43) | MAPTFFAR1PPARDPPARACEPT1 | |
| SCHEMBL15968100 | 0.88 | ACACB (0.49) | MAPTFFAR1PPARDPPARACEPT1 | |
| SCHEMBL15968648 | 0.87 | MAPT (0.41) | MAPTFFAR1PPARDPPARACEPT1 | |
| SCHEMBL15968649 | 0.86 | ACACA (0.51) | MAPTGPR119ACACBF2RL3 | |
| SCHEMBL15969010 | 0.84 | ACACB (0.46) | ACACBMAOAF2RL3 | |
| SCHEMBL15968555 | 0.83 | ACACA (0.46) | MAPTGPR119ACACB | |
| SCHEMBL15968187 | 0.83 | S1PR1 (0.41) | MAPTFFAR1PPARDPPARAS1PR1 | |
| SCHEMBL15968050 | 0.83 | MAPT (0.50) | MAPTGPR119LMNAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | MAPT 3593/4885FFAR1 3706/4885PPARD 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.